King Pharmaceuticals Financial Statements
King Pharmaceuticals Financial Information
| Company Type | Public Headquarters |
|---|---|
| Fiscal Year-End | December |
© 2009 Morningstar, Inc. Financial Data provided by
King Pharmaceuticals Income Statement
| 2008 | 2007 | 2006 | |
|---|---|---|---|
| Revenue ($ mil.) | 1,565.1 | 2,136.9 | 1,988.5 |
| Gross Profit ($ mil.) | 1,170.2 | 1,347.3 | 1,421.1 |
| Operating Income ($ mil.) | (193.8) | 258.6 | 434.2 |
| Total Net Income ($ mil.) | (333.1) | 183.0 | 288.9 |
| Diluted EPS (Net Income) | (1.37) | 0.75 | 1.19 |
King Pharmaceuticals Quarterly Statements
| Quarter Ending Jun 09 | Quarter Ending Mar 09 | Quarter Ending Mar 09 | |
|---|---|---|---|
| Revenue ($ mil.) | 445.0 | 429.1 | 429.1 |
| Gross Profit ($ mil.) | 288.9 | 278.1 | 278.1 |
| Operating Income ($ mil.) | 94.9 | 6.3 | 6.3 |
| Total Net Income ($ mil.) | 37.9 | (10.7) | (10.7) |
| Diluted EPS (Net Income) | 0.15 | (0.04) | (0.04) |
King Pharmaceuticals Stock Quote & Chart
11/09/09 16:01:56 EST •
NYSE •
11.42
•
 +0.2100
•
+1.8733 %
|
|---|
|
Quotes delayed 15 minutes for NASDAQ. 20 minutes for NYSE and AMEX. Market Data provided by Interactive Data. Powered and Implemented by Interactive Data Managed Solutions.
|
King Pharmaceuticals Financial Ratios
| Company | Industry Median |
Market Median1 |
|
|---|---|---|---|
| Price/Sales Ratio | 1.70 | 16.45 | 7.01 |
| Price/Earnings Ratio | (6.35) | 384.62 | 25.51 |
| Price/Book Ratio | 1.22 | 3.53 | 6.74 |
| Price/Cash Flow Ratio | 7.40 | 80.00 | 43.48 |
1 Public companies trading on the New York Stock Exchange, the American Stock Exchange, and the NASDAQ National Market.
Detailed King Pharmaceuticals Financial Ratios
King Pharmaceuticals Competitive Intelligence
| Cephalon | Elan | Forest Labs | |
|---|---|---|---|
| Annual Sales ($ mil.) | 1,974.6 | 1,000.2 | 3,922.8 |
| Employees | 2,780 | 1,687 | 5,225 |
| Market Cap ($ mil.) | 4,349.6 | 3,101.9 | 8,649.1 |
Competitive Landscape
